Your browser doesn't support javascript.
loading
Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma.
Hirano, Mitsuhito; Imai, Yoichi; Kaito, Yuta; Murayama, Takahiko; Sato, Kota; Ishida, Tadao; Yamamoto, Junichi; Ito, Takumi; Futami, Muneyoshi; Ri, Masaki; Yasui, Hiroshi; Denda, Tamami; Tanaka, Yukihisa; Ota, Yasunori; Nojima, Masanori; Kamikubo, Yasuhiko; Gotoh, Noriko; Iida, Shinsuke; Handa, Hiroshi; Tojo, Arinobu.
Affiliation
  • Hirano M; Division of Molecular Therapy, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Imai Y; Department of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. imaiyo-tky@umin.ac.jp.
  • Kaito Y; Division of Molecular Therapy, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Murayama T; Division of Cancer Cell Biology, Cancer Research Institute of Kanazawa University, Kanazawa, Japan.
  • Sato K; Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
  • Ishida T; Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
  • Yamamoto J; School of Life Science and Technology, Tokyo Institute of Technology, Tokyo, Japan.
  • Ito T; Department of Chemical Biology, Tokyo Medical University, Tokyo, Japan.
  • Futami M; Department of Chemical Biology, Tokyo Medical University, Tokyo, Japan.
  • Ri M; Division of Molecular Therapy, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Yasui H; Department of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Denda T; Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Tanaka Y; Department of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Ota Y; Project Division of Fundamental Study on Cutting Edge of Genome Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Nojima M; Department of Pathology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Kamikubo Y; Department of Pathology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Gotoh N; Department of Pathology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Iida S; Center for Translational Research/Division of Advanced Medicine Promotion The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Handa H; Laboratory of Oncology and Strategic Innovation, Laboratory Science, Graduate School of Medicine Kyoto University, Kyoto, Japan.
  • Tojo A; Division of Cancer Cell Biology, Cancer Research Institute of Kanazawa University, Kanazawa, Japan.
J Exp Clin Cancer Res ; 40(1): 110, 2021 Mar 23.
Article in En | MEDLINE | ID: mdl-33757580
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Angiogenesis Inhibitors / Histone Deacetylase Inhibitors / Immunotherapy / Multiple Myeloma Type of study: Prognostic_studies Limits: Animals / Female / Humans / Male Language: En Journal: J Exp Clin Cancer Res Year: 2021 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Angiogenesis Inhibitors / Histone Deacetylase Inhibitors / Immunotherapy / Multiple Myeloma Type of study: Prognostic_studies Limits: Animals / Female / Humans / Male Language: En Journal: J Exp Clin Cancer Res Year: 2021 Document type: Article Affiliation country: